Aegerion Pharmaceuticals Acknowledges the National Lipid Association's Revised Guidelines for the Treatment of Familial Hypercholesterolemia


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) today acknowledged the publication of the National Lipid Association's guidelines for the screening, diagnosis and treatment of familial hypercholesterolemia. There are six articles in total published in the April 2011 Journal of Clinical Lipidology summarizing the consensus opinion of the National Lipid Association's Expert Panel on Familial Hypercholesterolemia with respect to the prevalence of the disease and recommended clinical criteria for diagnosis and treatment of pediatric and adult patient populations across the spectrum of FH severity.Aegerion Pharmaceuticals is currently in late-stage clinical development with their drug candidate, Lomitapide, to treat genetic lipid disorders.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDA